The most recent evaluation of the extended-release/long-acting opioid products REMS reflects an ongoing and frustrating question for both FDA and the biopharma industry: How best to determine whether the risk management programs are truly working?
FDA's analysis of the assessment for the ER/LA Risk Evaluation and Mitigation Strategy suggests that three years after voluntary training...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?